Most Shorted Stocks
DNLI is part of our most shorted stocks screen list, indicating it has a high short interest.
DENALI THERAPEUTICS INC (DNLI) Stock Price & Overview
NASDAQ:DNLI • US24823R1059
Current stock price
20.315 USD
+0.19 (+0.92%)
Last:
The current stock price of DNLI is 20.315 USD. Today DNLI is up by 0.92%. In the past month the price decreased by -4.55%. In the past year, price increased by 28.38%.
DNLI Key Statistics
52-Week Range12.58 - 23.77
Current DNLI stock price positioned within its 52-week range.
1-Month Range17.86 - 23.46
Current DNLI stock price positioned within its 1-month range.
- Market Cap
- 3.222B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.97
- Dividend Yield
- N/A
DNLI Stock Performance
Today
+0.92%
1 Week
-0.15%
1 Month
-4.55%
3 Months
-0.59%
Longer-term
6 Months +26.13%
1 Year +28.38%
2 Years +30.38%
3 Years -18.96%
5 Years -66.69%
10 Years N/A
DNLI Stock Chart
DNLI Stock Screens
DNLI currently appears in the following ChartMill screener lists.
DNLI Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to DNLI. When comparing the yearly performance of all stocks, DNLI turns out to be only a medium performer in the overall market: it outperformed 66.03% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
DNLI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DNLI. The financial health of DNLI is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
DNLI Earnings
Next Earnings DateMay 4, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$0.73
Revenue Reported
EPS Surprise 3.82%
Revenue Surprise -100.00%
DNLI Forecast & Estimates
25 analysts have analysed DNLI and the average price target is 36.72 USD. This implies a price increase of 80.75% is expected in the next year compared to the current price of 20.315.
For the next year, analysts expect an EPS growth of 7.09% and a revenue growth 2718.14% for DNLI
Analysts
Analysts87.2
Price Target36.72 (80.75%)
EPS Next Y7.09%
Revenue Next Year2718.14%
DNLI Groups
Sector & Classification
DNLI Financial Highlights
Over the last trailing twelve months DNLI reported a non-GAAP Earnings per Share(EPS) of -2.97. The EPS decreased by -11.24% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-512.54M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.77% | ||
| ROE | -50.56% | ||
| Debt/Equity | 0.01 |
Chartmill High Growth Momentum
EPS Q2Q%-8.96%
Sales Q2Q%N/A
EPS 1Y (TTM)-11.24%
Revenue 1Y (TTM)N/A
DNLI Ownership
Ownership
Inst Owners97.49%
Shares158.59M
Float143.13M
Ins Owners4.26%
Short Float %10.77%
Short Ratio8.69
DNLI Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.56 | 362.808B | ||
| AMGN | AMGEN INC | 15.06 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 14.9 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.44 | 111.051B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.9 | 79.011B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.41 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.81 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.85 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DNLI
Company Profile
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 503 full-time employees. The company went IPO on 2017-12-08. The firm is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. The company has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). The company is also exploring programs in oncology, inflammation, and other diseases.
Company Info
IPO: 2017-12-08
DENALI THERAPEUTICS INC
161 Oyster Point Blvd.
South San Francisco CALIFORNIA 94080 US
CEO: Ryan J. Watts
Employees: 503
Phone: 16508668547
DENALI THERAPEUTICS INC / DNLI FAQ
What does DENALI THERAPEUTICS INC do?
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 503 full-time employees. The company went IPO on 2017-12-08. The firm is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. The company has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). The company is also exploring programs in oncology, inflammation, and other diseases.
Can you provide the latest stock price for DENALI THERAPEUTICS INC?
The current stock price of DNLI is 20.315 USD. The price increased by 0.92% in the last trading session.
What is the dividend status of DENALI THERAPEUTICS INC?
DNLI does not pay a dividend.
What is the ChartMill technical and fundamental rating of DNLI stock?
DNLI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of DENALI THERAPEUTICS INC (DNLI)?
DENALI THERAPEUTICS INC (DNLI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.97).
Should I buy DNLI stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DNLI.
Can you provide the market cap for DENALI THERAPEUTICS INC?
DENALI THERAPEUTICS INC (DNLI) has a market capitalization of 3.22B USD. This makes DNLI a Mid Cap stock.